Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Vitamin D deficiency was observed in 49% participants, with hyperhomocysteinemia in 34%, dual-risk in 22%, and executive dysfunction in 38% participants.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a single-center, prospective, cross-sectional study of inpatients aged ≥60 years with hypertension (November 2023: July 2024).

Source: Abstract.

Patients were ineligible if they had (i) acute stroke or TIA under evaluation or confirmed within the prior 30 days (neuroimaging/neurology note), (ii) current delirium by a standardized screen at the time of cognitive testing (3D-CAM on wards or CAM-ICU in monitored settings), (iii) deep/ongoing sedation [continuous sedative infusion or Richmond Agitation-Sedation Scale (RASS) ≤ −2], (iv) severe sensory/motor barriers precluding valid testing, or (v) inability to communicate in Mandarin/local dialect.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Association of serum 25-hydroxyvitamin D and homocysteine “double-risk” status with executive dysfunction in older adults with hypertension

Cross-sectional study · Frontiers in Nutrition · 2026

Original publication title

Association of serum 25-hydroxyvitamin D and homocysteine “double-risk” status with executive dysfunction in older adults with hypertension

Lili Tan; Linya Zhao; Hongyan Li; Yamin Zhao; Yinyin Chen

Copyright © 2026 Tan, Zhao, Li, Zhao and Chen.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In older hypertensive inpatients, lower 25(OH)D and higher homocysteine are non-linearly associated with executive dysfunction, and co-occurrence confers excess risk beyond individual effects. Assessing both biomarkers may enhance risk stratification and guide trials of combined correction.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Executive dysfunction in older adults with hypertension is a significant public health concern due to its impact on self-management and adverse health outcomes. Hypertension, prevalent in two-thirds of individuals over 60, is a major risk factor for cognitive decline, including executive dysfunction (1, 2). The cognitive decline associated with hypertension often affects the frontal lobe, leading to impairments in decision-making, planning, and organizing (3 to 5). Furthermore, cognitive impairments can hinder the ability of older adults to engage in health-promoting behaviors (6).

Effective management of hypertension in older adults requires an individualized approach that considers cognitive status (1, 7). Therefore, addressing executive dysfunction through interventions such as cognitive training, the use of organizational aids, and patient-centered care strategies could enhance self-management capabilities and improve health outcomes in older adults with hypertension (5, 8).

Low levels of 25-hydroxyvitamin D [25(OH)D] and elevated homocysteine (Hcy) are implicated in mechanisms that contribute to endothelial injury and white matter compromise, which are critical pathways affecting executive control. Elevated homocysteine levels, known as hyperhomocysteinemia (HHcy), are associated with oxidative stress, neuroinflammation, and endothelial dysfunction, all of which contribute to the disruption of the blood: brain barrier and neurodegeneration, thereby increasing the risk of neurovascular diseases such as stroke and vascular dementia (9, 10). HHcy is also linked to the pathogenesis of Alzheimer’s disease through mechanisms such as tau phosphorylation, beta-amyloid aggregation, and neurofibrillary tangle formation, which are exacerbated by oxidative stress and neuroinflammation (3, 10).

These processes highlight the role of HHcy in promoting vascular dysfunction and neurodegenerative changes, which are critical to the development of cognitive impairments (11, 12). On the other hand, vitamin D deficiency is associated with increased risks of cardiovascular and neurodegenerative diseases due to its role in maintaining endothelial function and reducing oxidative stress and inflammation (13). Low 25(OH)D levels are correlated with more severe white matter hyperintensities and cognitive decline (14). The neurovascular unit, which includes oligodendrocytes responsible for myelinating axons, is particularly vulnerable to ischemic damage, and vitamin D plays a protective role in maintaining myelin integrity and reducing white matter injury (15).

Thus, both low 25(OH)D and elevated Hcy contribute to vascular and neuroinflammatory pathways that compromise myelin integrity and cognitive function (16), and consistent with a cerebrovascular pathway, lower 25(OH)D has also been associated with higher stroke risk (17).

Building on evidence that vitamin D deficiency and hyperhomocysteinemia may affect vascular and white-matter pathways relevant to executive control, our objective was to characterize the associations of serum 25(OH)D and plasma Hcy with executive dysfunction and to test their joint effects on both multiplicative and additive scales in older hypertensive inpatients.

Source: Introduction Source: Introduction Source: Introduction

Study methods

What methods does the paper describe?

Study design and participants

We enrolled consecutive inpatients aged ≥60 years with physician-diagnosed hypertension between November 2023 and July 2024. The protocol was approved by the institutional ethics committee of the Affiliated Hospital of Hebei University, and all participants provided written informed consent. The study conformed to the Declaration of Helsinki and local regulations for human research.

Patients were ineligible if they had (i) acute stroke or TIA under evaluation or confirmed within the prior 30 days (neuroimaging/neurology note), (ii) current delirium by a standardized screen at the time of cognitive testing (3D-CAM on wards or CAM-ICU in monitored settings), (iii) deep/ongoing sedation [continuous sedative infusion or Richmond Agitation-Sedation Scale (RASS) ≤ −2], (iv) severe sensory/motor barriers precluding valid testing, or (v) inability to communicate in Mandarin/local dialect. Patients with remote ischemic stroke/TIA remained eligible with a history recorded for analysis.

Those with transient delirium or recent procedural sedation were deferred and re-approached once delirium screens were negative and washout criteria were met.

Setting and procedures

Participants were recruited from inpatient medical wards where admissions reflect the evaluation and management of hypertension and common comorbidities. Because acute delirium, active cardiorespiratory decompensation, or sedative medications can transiently affect cognitive performance, we applied prespecified acute-illness safeguards to ensure testing occurred under clinically stable conditions. All testing occurred within 72 h of admission and after acute-illness safeguards: examiners performed a brief neuro check and a delirium screen (3D-CAM/CAM-ICU) immediately pre-test. If an individual was positive, the test was postponed ≥24 h until two consecutive negative screens.

To minimize sedative carryover, assessments were scheduled ≥6 h after the last IV sedative/benzodiazepine/opioid dose and ≥12 h after the discontinuation of continuous infusions. Pre-test RASS had to be ≥−1. We abstracted sedation exposure from the medication administration record (any benzodiazepine/opioid in prior 24 h; propofol/dexmedetomidine infusion hours in prior 24 h). We captured acute-infection markers within 24 h of testing: temperature, WBC count, C-reactive protein (CRP), procalcitonin, antibiotic initiation and positive cultures: and cardiorespiratory decompensation proxies (SpO2, supplemental O2, systolic BP).

Exposures and laboratory measurements

Primary exposures were serum 25(OH)D and plasma total homocysteine, analyzed in the hospital’s central laboratory with internal quality control during each shift and quarterly external proficiency testing. Serum 25(OH)D was quantified using a chemiluminescent immunoassay on an automated analyzer (Beckman Coulter Access). Plasma total homocysteine was quantified using an enzymatic cycling assay (Diazyme Homocysteine Enzymatic Assay). Serum folate and vitamin B12 were measured using an Abbott ARCHITECT i. Serum creatinine was measured using Creatinine plus (CREP2) on cobas c/COBAS INTEGRA, and eGFR was calculated from creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

Whole blood was centrifuged for 2 h. Serum/plasma aliquots were analyzed on the day of draw. A priori, clinical cut points defined vitamin D deficiency as 25(OH)D < 20 ng/mL (18) and HHcy as homocysteine ≥15 μmol/L. These were combined into a four-level “dual-risk” variable (neither, vitamin D deficiency only, HHcy only, both). To adjust for seasonal variation in 25(OH)D, the calendar month of blood draw was categorized into winter, spring, summer, or autumn for covariate adjustment and sensitivity analyses.

Executive function (EF) was assessed with the Trail Making Test-B (TMT-B), Stroop Color-Word interference, Digit Symbol Substitution (DSST), and Category Fluency. Each raw score was converted to age−/education-adjusted normative T-scores (mean 50, SD 10) using published test norms appropriate for our setting. Directionality was aligned so higher T indicates better performance. The EF composite T-score was the mean of available component T-scores when ≥3 tests were valid. The primary binary outcome (executive dysfunction_norm) was composite T ≤ 40 (≥1 SD below norms, consistent with mild executive impairment), with T ≤ 35 examined as a more stringent threshold in sensitivity analyses.

To facilitate comparability with prior inpatient studies, we also constructed a sample-standardized composite z-score and defined executive dysfunction_z as z ≤ −0.3; this moved to a prespecified sensitivity analysis. All scoring was reviewed by a supervising neuropsychologist.

Covariates

The prespecified adjustment set retained age, sex, education, BMI, systolic BP, diabetes, eGFR modeled continuously with restricted cubic splines, smoking, vitamin D supplementation, B-vitamin supplementation, and season of draw. To address acute-care context, we specified context-robust models that additionally included: history of ischemic stroke/TIA (yes/no), sedation exposure (any benzodiazepine/opioid in prior 24 h or any sedative infusion in prior 24 h; yes/no), and infection burden captured as a composite indicator (fever ≥38.0 °C, WBC ≥ 12 × 109/L, CRP ≥ 10 mg/L, procalcitonin ≥0.25 ng/mL, or new systemic antibiotics within 24 h; yes/no).

These variables were abstracted from the EHR around the cognitive testing timestamp.

Statistical analysis

Baseline characteristics were summarized using means with standard deviations (SDs) or medians with interquartile ranges (IQRs) for continuous variables and counts with whole-number percentages for categorical variables. Group differences were determined using ANOVA or Kruskal: Wallis tests for continuous variables and χ2 tests for categorical variables, with Benjamini: Hochberg false discovery rate (FDR). Primary analyses modeled associations of 25(OH)D and Hcy with executive dysfunction using multivariable logistic regression with restricted cubic splines (RCS; four knots at Harrell percentiles: 5th, 35th, 65th, and 95th), fixing reference values at 30 ng/mL for 25(OH)D and 10 μmol/L for Hcy.

Joint effects were estimated with the four-level exposure, and multiplicative interaction was tested via a product term in fully adjusted models. Additive interaction was quantified from robust Poisson regression with log link and sandwich variance to estimate relative risks and derive the relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (S) with 95% CIs via the delta method. Model diagnostics included inspection of leverage and influence (Δβ and Cook’s distance), assessment of multicollinearity (variance inflation factors <2), and checks for spline overfitting by comparing Akaike information criteria across knot specifications.

Two-sided α = 0.05 defined statistical significance, and analyses were performed in R (Version 4.4).

Sensitivity analyses

Robustness was evaluated by varying the executive dysfunction threshold to composite z ≤ −0.5 and ≤ −0.7, altering spline flexibility by moving knots to quintiles and, separately, refitting with three and five knots, trimming extreme biomarker values by excluding the <1st and >99th percentiles, excluding users of vitamin D and, separately, B-vitamin supplements, and expanding the adjustment set to include folate and vitamin B12 concentrations. The direction and magnitude of primary inferences were stable across these checks.

Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods

Results: Participant flow and sample characteristics

Of 498 admissions screened, 486 individuals were eligible, 462 consented, and 452 were included in the analytic cohort after exclusion for incomplete cognitive testing (n = 6) and unusable assays (n = 4) (Figure 1). The mean age was 72 ± 7 years, and 53% were women. Vitamin D deficiency occurred in 49% (n = 222), hyperhomocysteinemia in 34% (n = 155), and dual-risk in 22% (n = 99), while executive dysfunction prevalence was 38% (n = 172) (Table 1).

Counts across the four dual-risk categories were: neither in 174, vitamin D deficiency in 123, hyperhomocysteinemia in 56, and both in 99 (Table 1).

Figure 1

Study flow diagram. Flow of participants from screening to analysis. Final analytic sample n = 452.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Baseline characteristics by vitamin D/homocysteine dual-risk categories.

CharacteristicOverall (n = 452)Neither (n = 174)VitD-only (n = 123)HHcy-only (n = 56)Both (n = 99) p q
Age, y (mean ± SD)72 ± 771 ± 672 ± 674 ± 773 ± 70.040.06
Female, n (%)240 (53%)100 (57%)73 (59%)20 (36%)47 (48%)0.0030.01
Education ≤9 y, n (%)238 (53%)80 (46%)70 (57%)31 (55%)57 (58%)0.020.04
BMI, kg/m2 (mean ± SD)25 ± 425 ± 425 ± 425 ± 424 ± 40.110.15
SBP, mmHg (mean ± SD)142 ± 17141 ± 16143 ± 17144 ± 18145 ± 180.090.13
Diabetes, n (%)124 (27%)40 (23%)36 (29%)17 (30%)31 (31%)0.140.18
Chronic kidney disease, n (%)91 (20%)27 (16%)23 (19%)15 (27%)26 (26%)0.010.03
Current smoker, n (%)98 (22%)31 (18%)22 (18%)20 (36%)25 (25%)0.0040.01
Vitamin B12, pmol/L [median (IQR)]340 [260 to 460]352 [272 to 466]338 [252 to 450]320 [238 to 430]312 [232 to 420]0.080.12
Folate, ng/mL [median (IQR)]7.8 [5.6 to 10.2]8.0 [6.0 to 10.5]7.6 [5.4 to 9.9]7.2 [5.1 to 9.5]7.0 [4.9 to 9.3]0.0480.07
eGFR, mL/min/1.73 m2 [median (IQR)]74 [61 to 86]77 [64 to 89]73 [60 to 85]70 [57 to 82]69 [56 to 81]0.0070.02
25(OH)D, ng/mL [median (IQR)]21.4 [14.8 to 28.3]27.6 [23.1 to 33.9]14.6 [11.9 to 17.6]26.0 [20.8 to 31.8]13.8 [11.1 to 17.1]<0.001<0.001
Homocysteine, μmol/L [median (IQR)]14.2 [11.0 to 18.7]11.2 [9.4 to 12.7]12.1 [10.3 to 14.3]18.1 [16.2 to 21.8]19.3 [16.8 to 23.7]<0.001<0.001
Vitamin D supplement use, n (%)66 (15%)32 (18%)8 (7%)10 (18%)16 (16%)0.0030.01
B-vitamin supplement use, n (%)57 (13%)19 (11%)12 (10%)12 (21%)14 (14%)0.030.048
Executive dysfunction, n (%)172 (38%)47 (27%)48 (39%)20 (36%)57 (58%)<0.001<0.001

VitD-only, vitamin D deficiency only; HHcy-only, hyperhomocysteinemia only; eGFR, estimated glomerular filtration rate (mL/min/1.73 m2).

Source: Participant flow and sample characteristics Source: Participant flow and sample characteristics Source: Participant flow and sample characteristics

Baseline characteristics across dual-risk categories

Results: Baseline characteristics across dual-risk categories

Participants with both risks had higher current smoking (25%) and CKD (eGFR <60 mL/min/1.73 m2) prevalence (26%) and lower eGFR [median 69 mL/min/1.73 m2 (56 to 81)] than those with neither risk [current smoking 18%; CKD 16%; eGFR 77 mL/min/1.73 m2 (64 to 89); p = 0.004, 0.01, and 0.007; FDR-adjusted q = 0.01, 0.03, and 0.02]. Women were less prevalent in the hyperhomocysteinemia-only group (36%), contributing to overall sex differences (p = 0.003; q = 0.01). Folate and vitamin B12 trended lower with increasing risk burden (folate p = 0.048; q = 0.070; B12 p = 0.08; q = 0.12), and supplementation patterns were imbalanced, with fewer vitamin D supplement users in the vitamin D-deficient only group (7%) and more B-vitamin use in the hyperhomocysteinemia-only group (21%; p = 0.003 and 0.03; q = 0.01 and 0.048).

As constructed, 25(OH)D and Hcy levels showed marked gradients across categories (both p < 0.001; q < 0.001). Executive dysfunction prevalence rose stepwise from 27% in the neither group to 39% in vitamin D deficiency only, 36% in hyperhomocysteinemia only, and 58% in the dual-risk group (p < 0.001; q < 0.001), matching a priori risk expectations (Table 1).

Table 1

Baseline characteristics by vitamin D/homocysteine dual-risk categories.

CharacteristicOverall (n = 452)Neither (n = 174)VitD-only (n = 123)HHcy-only (n = 56)Both (n = 99) p q
Age, y (mean ± SD)72 ± 771 ± 672 ± 674 ± 773 ± 70.040.06
Female, n (%)240 (53%)100 (57%)73 (59%)20 (36%)47 (48%)0.0030.01
Education ≤9 y, n (%)238 (53%)80 (46%)70 (57%)31 (55%)57 (58%)0.020.04
BMI, kg/m2 (mean ± SD)25 ± 425 ± 425 ± 425 ± 424 ± 40.110.15
SBP, mmHg (mean ± SD)142 ± 17141 ± 16143 ± 17144 ± 18145 ± 180.090.13
Diabetes, n (%)124 (27%)40 (23%)36 (29%)17 (30%)31 (31%)0.140.18
Chronic kidney disease, n (%)91 (20%)27 (16%)23 (19%)15 (27%)26 (26%)0.010.03
Current smoker, n (%)98 (22%)31 (18%)22 (18%)20 (36%)25 (25%)0.0040.01
Vitamin B12, pmol/L [median (IQR)]340 [260 to 460]352 [272 to 466]338 [252 to 450]320 [238 to 430]312 [232 to 420]0.080.12
Folate, ng/mL [median (IQR)]7.8 [5.6 to 10.2]8.0 [6.0 to 10.5]7.6 [5.4 to 9.9]7.2 [5.1 to 9.5]7.0 [4.9 to 9.3]0.0480.07
eGFR, mL/min/1.73 m2 [median (IQR)]74 [61 to 86]77 [64 to 89]73 [60 to 85]70 [57 to 82]69 [56 to 81]0.0070.02
25(OH)D, ng/mL [median (IQR)]21.4 [14.8 to 28.3]27.6 [23.1 to 33.9]14.6 [11.9 to 17.6]26.0 [20.8 to 31.8]13.8 [11.1 to 17.1]<0.001<0.001
Homocysteine, μmol/L [median (IQR)]14.2 [11.0 to 18.7]11.2 [9.4 to 12.7]12.1 [10.3 to 14.3]18.1 [16.2 to 21.8]19.3 [16.8 to 23.7]<0.001<0.001
Vitamin D supplement use, n (%)66 (15%)32 (18%)8 (7%)10 (18%)16 (16%)0.0030.01
B-vitamin supplement use, n (%)57 (13%)19 (11%)12 (10%)12 (21%)14 (14%)0.030.048
Executive dysfunction, n (%)172 (38%)47 (27%)48 (39%)20 (36%)57 (58%)<0.001<0.001

VitD-only, vitamin D deficiency only; HHcy-only, hyperhomocysteinemia only; eGFR, estimated glomerular filtration rate (mL/min/1.73 m2).

Source: Baseline characteristics across dual-risk categories Source: Baseline characteristics across dual-risk categories

Non-linear dose: response associations of biomarkers with executive dysfunction

Results: Non-linear dose: response associations of biomarkers with executive dysfunction

Restricted cubic spline models demonstrated non-linear relationships between both biomarkers and executive dysfunction after multivariable adjustment (Table 2, Figure 2). For 25(OH)D, the global non-linearity test was significant (p = 0.02; q = 0.03), with risk increasing steeply below approximately 20 ng/mL and flattening above 30 to 40 ng/mL. Relative to 30 ng/mL, the adjusted OR at 15 ng/mL was 1.6 (95% CI 1.2 to 2.2; p = 0.003; q = 0.009), and at 10 ng/mL the OR reached 2.0 (1.3 to 2.9).

For homocysteine, non-linearity was also significant (p = 0.04; q = 0.049), with relatively flat risk at lower concentrations and a monotonic rise beyond approximately 15 μmol/L; the adjusted OR at 18 μmol/L vs. 10 μmol/L was 1.4 (1.1 to 2.0; p = 0.02; q = 0.048), increasing to 1.7 (1.1 to 2.5) at 22 μmol/L.

Table 2

Associations of 25(OH)D and homocysteine with executive dysfunction.

Exposure and specificationAdjusted OR (95% CI) p q
Non-linear dose: response (RCS; 4 knots)Not reported0.020.03
25(OH)D: test of non-linearityNot reported0.040.049
Hcy: test of non-linearity
Prespecified contrasts (continuous)1.6 (1.2 to 2.2)0.0030.009
25(OH)D 15 vs. 30 ng/mL1.4 (1.1 to 2.0)0.020.048
Hcy 18 vs. 10 μmol/L
Binary categories1.5 (1.1 to 2.2)0.020.03
Vitamin D deficiency (<20 vs. ≥20 ng/mL)1.4 (1.0 to 2.0)0.0450.06
Hyperhomocysteinemia (≥15 vs. <15 μmol/L)
Four-level dual-risk (ref = Neither)1.4 (1.0 to 2.0)0.070.08
VitD-only1.3 (0.8 to 2.1)0.230.23
HHcy-only2.1 (1.5 to 2.9)<0.001<0.001
Both (double-risk)Not reported0.030.04
Multiplicative interaction (product term)Not reported0.020.03

CI, confidence interval; HHcy, hyperhomocysteinemia; OR, odds ratio; RCS, restricted cubic splines.

Figure 2

(A) Non-linear association of 25(OH)D with executive dysfunction. Adjusted odds ratios (ORs) from logistic models with restricted cubic splines (four knots); reference fixed at 30 ng/mL. Shaded band: 95% CI. Test of non-linearity p = 0.02; prespecified contrast 15 vs. 30 ng/mL OR 1.6 (95% CI 1.2 to 2.2). Covariates as in Methods. (B) Non-linear association of homocysteine with executive dysfunction. Adjusted ORs from spline models; reference 10 μmol/L. Shaded band: 95% CI. Test of non-linearity p = 0.04; prespecified contrast 18 vs. 10 μmol/L OR 1.4 (95% CI 1.1 to 2.0). 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio; CI, confidence interval.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Non-linear dose: response associations of biomarkers with executive dysfunction Source: Non-linear dose: response associations of biomarkers with executive dysfunction Source: Non-linear dose: response associations of biomarkers with executive dysfunction

Joint effects of vitamin D deficiency and hyperhomocysteinemia

Results: Joint effects of vitamin D deficiency and hyperhomocysteinemia

Relative to participants with neither risk, those with both risks exhibited more than 2-fold higher odds of executive dysfunction (adjusted OR 2.1, 95% CI 1.5 to 2.9; p < 0.001; q < 0.001), whereas point estimates were smaller and not statistically significant for the single-risk categories (vitamin D deficiency only OR 1.4, 95% CI 1.0 to 2.0; p = 0.07; q = 0.08; hyperhomocysteinemia only OR 1.3, 95% CI 0.8 to 2.1; p = 0.23; q = 0.23). A formal product-term test supported multiplicative interaction between deficiency and hyperhomocysteinemia (p = 0.03; q = 0.04).

Translating relative to absolute risk at the sample-mean covariate profile, predicted executive dysfunction probabilities were 29% (95% CI 23 to 35) for neither, 37% (30 to 44) for vitamin D deficiency only, 35% (26 to 45) for hyperhomocysteinemia only, and 52% (43 to 61) for both (Figure 3).

Figure 3

Joint effects of vitamin D deficiency and hyperhomocysteinemia on executive dysfunction. Forest plot shows adjusted ORs (95% CI) for four exposure categories (reference: neither risk), with marginal predicted executive dysfunction probabilities annotated. Double-risk OR 2.1 (95% CI 1.5 to 2.9); multiplicative interaction p = 0.03. executive dysfunction; OR, odds ratio; CI, confidence interval.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Joint effects of vitamin D deficiency and hyperhomocysteinemia Source: Joint effects of vitamin D deficiency and hyperhomocysteinemia

Results: Additive interaction

On the additive scale, robust Poisson models indicated positive biological interaction between vitamin D deficiency and HHcy (Table 3). The relative excess risk due to interaction (RERI) was 0.45 (95% CI 0.06 to 0.95; p = 0.03; q = 0.04), the attributable proportion (AP) was 0.22 (0.03 to 0.39; p = 0.03; q = 0.04), and the synergy index (S) was 1.5 (1.1 to 2.1; p = 0.03; q = 0.04), indicating that approximately one-fifth of risk among dually exposed patients reflects excess risk beyond the sum of individual effects (Table 3, Figure 3).

Table 3

Additive interaction between vitamin D deficiency and hyperhomocysteinemia for executive dysfunction.

Metric (ref = Neither)Estimate (95% CI) p q
RERI (excess risk due to interaction)0.45 (0.06 to 0.95)0.030.04
Attributable proportion (AP)0.22 (0.03 to 0.39)0.030.04
Synergy index (S)1.5 (1.1 to 2.1)0.030.04

Executive dysfunction; CI, confidence interval; RERI, relative excess risk due to interaction; AP, attributable proportion; S, synergy index.

Source: Additive interaction Source: Additive interaction

Discussion

In this cross-sectional cohort study, we found that both lower 25(OH)D and higher Hcy were related to executive dysfunction in distinctly non-linear patterns. Crucially, when both abnormalities co-occurred (“double-risk”), the association exceeded individual effects: compared with patients with neither risk, the double-risk group had more than 2-fold higher odds of executive dysfunction.

Placed alongside prior studies, our results extend observational associations between low 25(OH)D and poorer executive performance and faster decline, and between higher Hcy and heavier cSVD/white-matter burdens, by revealing where along each continuum risk accelerates and by quantifying biological interaction between the two pathways (19 to 25). Studies in community and patient cohorts link low 25(OH)D to worse cognition and increased dementia risk, while neuroimaging reports connect low 25(OH)D and high Hcy to more white-matter hyperintensities and microstructural compromise: lesions that map onto executive control networks (19 to 25).

Methodologically, modeling with restricted cubic splines avoids the information loss and bias of linear or dichotomized exposures and makes the inflection zones explicit, and estimating additive-scale interaction (RERI, attributable proportion, synergy index) addresses whether the “double-risk” exceeds the sum of individual effects (26 to 28). Our spline-based contrasts and significant additive/multiplicative interaction, therefore, add granularity beyond much of the existing vitamin D/Hcy: cognition literature.

Clinically, our data support early inpatient assessment of both biomarkers in older adults with hypertension to refine cognitive risk stratification and to identify patients most likely to benefit from intervention (18, 29 to 33). In hypertensive populations, achieving 25(OH)D status has been linked to blood pressure measures in community supplement programs (34), and meta-analytic evidence suggests vitamin D supplementation may modestly reduce systolic blood pressure in hypertensive individuals with hypovitaminosis D (35). For homocysteine-lowering, the China Stroke Primary Prevention Trial (CSPPT) randomized hypertensive adults to enalapril plus folic acid vs. enalapril alone and reported reduced first stroke, whereas the Heart Outcomes Prevention Evaluation-2 (HOPE-2) trial tested folic acid/B-vitamin therapy in vascular disease and reported mixed cardiovascular outcomes but fewer strokes (36, 37).

Recent randomized controlled trial evidence suggests vitamin D supplementation does not improve executive function in older adults with mild cognitive impairment (38), and a recent meta-analysis suggests B-vitamin supplementation may have small effects on global cognitive function in older adults (39). Together, these data motivate factorial trials testing simultaneous vitamin D repletion and homocysteine-lowering on executive outcomes (and MRI white-matter endpoints) on top of guideline blood pressure control, enriched for patients who exhibit the dual-risk pattern.

Our findings point to a vascular-white-matter pathway linking both low 25(OH)D and elevated Hcy to executive dysfunction in older adults with hypertension. Risk rose steeply once 25(OH)D dropped into deficient ranges and as Hcy exceeded clinically used cutpoints, consistent with the biology that vitamin D restrains renin: angiotensin signaling and supports endothelial nitric oxide bioavailability, whereas Hcy impairs the nitric-oxide pathway via asymmetric dimethylarginine, promoting endothelial injury and prothrombotic tone (29 to 32). In cerebral small-vessel disease, endothelial failure, blood: brain barrier leak, and hypoperfusion render frontal: subcortical white matter especially vulnerable, providing a substrate for executive dysfunction (40 to 43).

This mechanistic arc explains the non-linear dose: response we observed for both biomarkers and the excess risk when deficiency and hyperhomocysteinemia co-occur, with predicted executive dysfunction probabilities rising from 29% (neither risk) to 52% (double-risk) in our cohort. The inflection zones align with widely adopted thresholds [25(OH)D < 20 ng/mL; Hcy ≥ 15 μmol/L] at which endothelial and white-matter injury patterns intensify (18, 29 to 33, 40 to 43).

Nonetheless, limitations warrant a cautious interpretation of our findings. The cross-sectional design precludes causal inference and leaves open reverse causation (e.g., illness severity influencing nutritional status or homocysteine). Residual confounding remains possible despite adjustment (e.g., sun exposure, dietary folate/B12, parathyroid hormone, and inflammatory status). Findings derive from a single-center inpatient population and may not generalize to community or outpatient settings. Single-time biomarker measurements are vulnerable to short-term variability and seasonality despite seasonal adjustment and sensitivity analyses. Complete-case primary models, with multiple imputation as a check, reduce but cannot eliminate bias from missingness.

Taken together, these strengths support the credibility of the observed non-linear associations and dual-scale interaction, while the limitations emphasize the need for multicenter, longitudinal studies with repeated biomarker assessments and mechanistic imaging to establish temporality and transportability.

In older hypertensive inpatients, lower 25-hydroxyvitamin D and higher homocysteine relate to executive dysfunction in non-linear patterns, and their co-occurrence confers excess risk beyond individual effects. Early inpatient assessment of both biomarkers can refine cognitive risk stratification and highlight patients most likely to benefit from targeted therapy. These findings support multicenter longitudinal studies and randomized factorial trials testing combined vitamin D repletion and homocysteine-lowering alongside guideline blood-pressure control.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

Participant flow and sample characteristics

Of 498 admissions screened, 486 individuals were eligible, 462 consented, and 452 were included in the analytic cohort after exclusion for incomplete cognitive testing (n = 6) and unusable assays (n = 4) (Figure 1). The mean age was 72 ± 7 years, and 53% were women. Vitamin D deficiency occurred in 49% (n = 222), hyperhomocysteinemia in 34% (n = 155), and dual-risk in 22% (n = 99), while executive dysfunction prevalence was 38% (n = 172) (Table 1).

Counts across the four dual-risk categories were: neither in 174, vitamin D deficiency in 123, hyperhomocysteinemia in 56, and both in 99 (Table 1).

Figure 1

Study flow diagram. Flow of participants from screening to analysis. Final analytic sample n = 452.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Baseline characteristics by vitamin D/homocysteine dual-risk categories.

CharacteristicOverall (n = 452)Neither (n = 174)VitD-only (n = 123)HHcy-only (n = 56)Both (n = 99) p q
Age, y (mean ± SD)72 ± 771 ± 672 ± 674 ± 773 ± 70.040.06
Female, n (%)240 (53%)100 (57%)73 (59%)20 (36%)47 (48%)0.0030.01
Education ≤9 y, n (%)238 (53%)80 (46%)70 (57%)31 (55%)57 (58%)0.020.04
BMI, kg/m2 (mean ± SD)25 ± 425 ± 425 ± 425 ± 424 ± 40.110.15
SBP, mmHg (mean ± SD)142 ± 17141 ± 16143 ± 17144 ± 18145 ± 180.090.13
Diabetes, n (%)124 (27%)40 (23%)36 (29%)17 (30%)31 (31%)0.140.18
Chronic kidney disease, n (%)91 (20%)27 (16%)23 (19%)15 (27%)26 (26%)0.010.03
Current smoker, n (%)98 (22%)31 (18%)22 (18%)20 (36%)25 (25%)0.0040.01
Vitamin B12, pmol/L [median (IQR)]340 [260 to 460]352 [272 to 466]338 [252 to 450]320 [238 to 430]312 [232 to 420]0.080.12
Folate, ng/mL [median (IQR)]7.8 [5.6 to 10.2]8.0 [6.0 to 10.5]7.6 [5.4 to 9.9]7.2 [5.1 to 9.5]7.0 [4.9 to 9.3]0.0480.07
eGFR, mL/min/1.73 m2 [median (IQR)]74 [61 to 86]77 [64 to 89]73 [60 to 85]70 [57 to 82]69 [56 to 81]0.0070.02
25(OH)D, ng/mL [median (IQR)]21.4 [14.8 to 28.3]27.6 [23.1 to 33.9]14.6 [11.9 to 17.6]26.0 [20.8 to 31.8]13.8 [11.1 to 17.1]<0.001<0.001
Homocysteine, μmol/L [median (IQR)]14.2 [11.0 to 18.7]11.2 [9.4 to 12.7]12.1 [10.3 to 14.3]18.1 [16.2 to 21.8]19.3 [16.8 to 23.7]<0.001<0.001
Vitamin D supplement use, n (%)66 (15%)32 (18%)8 (7%)10 (18%)16 (16%)0.0030.01
B-vitamin supplement use, n (%)57 (13%)19 (11%)12 (10%)12 (21%)14 (14%)0.030.048
Executive dysfunction, n (%)172 (38%)47 (27%)48 (39%)20 (36%)57 (58%)<0.001<0.001

VitD-only, vitamin D deficiency only; HHcy-only, hyperhomocysteinemia only; eGFR, estimated glomerular filtration rate (mL/min/1.73 m2).

Baseline characteristics across dual-risk categories

Participants with both risks had higher current smoking (25%) and CKD (eGFR <60 mL/min/1.73 m2) prevalence (26%) and lower eGFR [median 69 mL/min/1.73 m2 (56 to 81)] than those with neither risk [current smoking 18%; CKD 16%; eGFR 77 mL/min/1.73 m2 (64 to 89); p = 0.004, 0.01, and 0.007; FDR-adjusted q = 0.01, 0.03, and 0.02]. Women were less prevalent in the hyperhomocysteinemia-only group (36%), contributing to overall sex differences (p = 0.003; q = 0.01). Folate and vitamin B12 trended lower with increasing risk burden (folate p = 0.048; q = 0.070; B12 p = 0.08; q = 0.12), and supplementation patterns were imbalanced, with fewer vitamin D supplement users in the vitamin D-deficient only group (7%) and more B-vitamin use in the hyperhomocysteinemia-only group (21%; p = 0.003 and 0.03; q = 0.01 and 0.048).

As constructed, 25(OH)D and Hcy levels showed marked gradients across categories (both p < 0.001; q < 0.001). Executive dysfunction prevalence rose stepwise from 27% in the neither group to 39% in vitamin D deficiency only, 36% in hyperhomocysteinemia only, and 58% in the dual-risk group (p < 0.001; q < 0.001), matching a priori risk expectations (Table 1).

Non-linear dose: response associations of biomarkers with executive dysfunction

Restricted cubic spline models demonstrated non-linear relationships between both biomarkers and executive dysfunction after multivariable adjustment (Table 2, Figure 2). For 25(OH)D, the global non-linearity test was significant (p = 0.02; q = 0.03), with risk increasing steeply below approximately 20 ng/mL and flattening above 30 to 40 ng/mL. Relative to 30 ng/mL, the adjusted OR at 15 ng/mL was 1.6 (95% CI 1.2 to 2.2; p = 0.003; q = 0.009), and at 10 ng/mL the OR reached 2.0 (1.3 to 2.9).

For homocysteine, non-linearity was also significant (p = 0.04; q = 0.049), with relatively flat risk at lower concentrations and a monotonic rise beyond approximately 15 μmol/L; the adjusted OR at 18 μmol/L vs. 10 μmol/L was 1.4 (1.1 to 2.0; p = 0.02; q = 0.048), increasing to 1.7 (1.1 to 2.5) at 22 μmol/L.

Table 2

Associations of 25(OH)D and homocysteine with executive dysfunction.

Exposure and specificationAdjusted OR (95% CI) p q
Non-linear dose: response (RCS; 4 knots)Not reported0.020.03
25(OH)D: test of non-linearityNot reported0.040.049
Hcy: test of non-linearity
Prespecified contrasts (continuous)1.6 (1.2 to 2.2)0.0030.009
25(OH)D 15 vs. 30 ng/mL1.4 (1.1 to 2.0)0.020.048
Hcy 18 vs. 10 μmol/L
Binary categories1.5 (1.1 to 2.2)0.020.03
Vitamin D deficiency (<20 vs. ≥20 ng/mL)1.4 (1.0 to 2.0)0.0450.06
Hyperhomocysteinemia (≥15 vs. <15 μmol/L)
Four-level dual-risk (ref = Neither)1.4 (1.0 to 2.0)0.070.08
VitD-only1.3 (0.8 to 2.1)0.230.23
HHcy-only2.1 (1.5 to 2.9)<0.001<0.001
Both (double-risk)Not reported0.030.04
Multiplicative interaction (product term)Not reported0.020.03

CI, confidence interval; HHcy, hyperhomocysteinemia; OR, odds ratio; RCS, restricted cubic splines.

Figure 2

(A) Non-linear association of 25(OH)D with executive dysfunction. Adjusted odds ratios (ORs) from logistic models with restricted cubic splines (four knots); reference fixed at 30 ng/mL. Shaded band: 95% CI. Test of non-linearity p = 0.02; prespecified contrast 15 vs. 30 ng/mL OR 1.6 (95% CI 1.2 to 2.2). Covariates as in Methods. (B) Non-linear association of homocysteine with executive dysfunction. Adjusted ORs from spline models; reference 10 μmol/L. Shaded band: 95% CI. Test of non-linearity p = 0.04; prespecified contrast 18 vs. 10 μmol/L OR 1.4 (95% CI 1.1 to 2.0). 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio; CI, confidence interval.

Figure image at the original source: open the original paper. This file is not included in this text import.

Joint effects of vitamin D deficiency and hyperhomocysteinemia

Relative to participants with neither risk, those with both risks exhibited more than 2-fold higher odds of executive dysfunction (adjusted OR 2.1, 95% CI 1.5 to 2.9; p < 0.001; q < 0.001), whereas point estimates were smaller and not statistically significant for the single-risk categories (vitamin D deficiency only OR 1.4, 95% CI 1.0 to 2.0; p = 0.07; q = 0.08; hyperhomocysteinemia only OR 1.3, 95% CI 0.8 to 2.1; p = 0.23; q = 0.23). A formal product-term test supported multiplicative interaction between deficiency and hyperhomocysteinemia (p = 0.03; q = 0.04).

Translating relative to absolute risk at the sample-mean covariate profile, predicted executive dysfunction probabilities were 29% (95% CI 23 to 35) for neither, 37% (30 to 44) for vitamin D deficiency only, 35% (26 to 45) for hyperhomocysteinemia only, and 52% (43 to 61) for both (Figure 3).

Figure 3

Joint effects of vitamin D deficiency and hyperhomocysteinemia on executive dysfunction. Forest plot shows adjusted ORs (95% CI) for four exposure categories (reference: neither risk), with marginal predicted executive dysfunction probabilities annotated. Double-risk OR 2.1 (95% CI 1.5 to 2.9); multiplicative interaction p = 0.03. executive dysfunction; OR, odds ratio; CI, confidence interval.

Figure image at the original source: open the original paper. This file is not included in this text import.

Additive interaction

On the additive scale, robust Poisson models indicated positive biological interaction between vitamin D deficiency and HHcy (Table 3). The relative excess risk due to interaction (RERI) was 0.45 (95% CI 0.06 to 0.95; p = 0.03; q = 0.04), the attributable proportion (AP) was 0.22 (0.03 to 0.39; p = 0.03; q = 0.04), and the synergy index (S) was 1.5 (1.1 to 2.1; p = 0.03; q = 0.04), indicating that approximately one-fifth of risk among dually exposed patients reflects excess risk beyond the sum of individual effects (Table 3, Figure 3).

Table 3

Additive interaction between vitamin D deficiency and hyperhomocysteinemia for executive dysfunction.

Metric (ref = Neither)Estimate (95% CI) p q
RERI (excess risk due to interaction)0.45 (0.06 to 0.95)0.030.04
Attributable proportion (AP)0.22 (0.03 to 0.39)0.030.04
Synergy index (S)1.5 (1.1 to 2.1)0.030.04

Executive dysfunction; CI, confidence interval; RERI, relative excess risk due to interaction; AP, attributable proportion; S, synergy index.

Sensitivity analyses

Robustness checks confirmed that the main inferences did not depend on the outcome definition, kidney-function covariate, or inpatient context (Supplementary Tables S1, S2) (Supplementary Tables S1, S2). Using stricter executive dysfunction thresholds (z ≤ −0.5 and z ≤ −0.7) yielded the same non-linear patterns for both biomarkers [25(OH)D non-linearity p = 0.02 to 0.01; Hcy p = 0.04 to 0.03; all q ≤ 0.05] with contrasts similar to the primary analysis: 25(OH)D 15 vs. 30 ng/mL OR 1.6 to 1.7 and Hcy 18 vs. 10 μmol/L OR 1.4 to 1.5: and preserved the joint “double-risk” association (OR 2.1 to 2.2) together with multiplicative interaction (p = 0.03 to 0.02; q ≤ 0.05) and positive additive interaction (RERI 0.47 to 0.55) (Supplementary Tables S1, Panel A).

Representing renal function as CKD (eGFR<60 mL/min/1.73 m2) instead of the eGFR-spline produced materially similar estimates [25(OH)D OR 1.6; Hcy OR 1.4; double-risk OR 2.0; product-term p = 0.04; RERI 0.44], supporting the choice to model kidney function once, continuously (Supplementary Tables S1, Panel B). Context-robust models that added prior stroke/TIA, recent sedation exposure, and infection burden, as well as a restricted analysis excluding any sedation/infection in the prior 24 h, closely matched the primary results [25(OH)D OR 1.6 to 1.7; Hcy OR 1.4 to 1.5; double-risk OR 2.0 to 2.1; product-term p = 0.03 to 0.02; RERI 0.43 to 0.47], indicating that acute-care factors did not account for the observed non-linear associations or the excess risk in the double-risk group (Supplementary Table S2).

Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Abstract: Conclusion

In older hypertensive inpatients, lower 25(OH)D and higher homocysteine are non-linearly associated with executive dysfunction, and co-occurrence confers excess risk beyond individual effects. Assessing both biomarkers may enhance risk stratification and guide trials of combined correction.

Source: Conclusion
Authors’ abstract

Background

Executive dysfunction is common in adults with hypertension and undermines self-management. Low 25-hydroxyvitamin D [25(OH)D] and elevated homocysteine may damage the endothelium and white matter, while their non-linear dose: response and joint effects on executive dysfunction are unclear.

Methods

We conducted a single-center, prospective, cross-sectional study of inpatients aged ≥60 years with hypertension (November 2023: July 2024). Exposures were vitamin D deficiency [25(OH)D < 20 ng/mL] and hyperhomocysteinemia (hymocysteine ≥15 μmol/L), combined into a four-level dual-risk variable. Executive function was a composite of four tests. Non-linear associations were estimated with logistic regression using restricted cubic splines. Multiplicative interaction was assessed after adjustment for demographic, clinical, renal, lifestyle, supplementation, and seasonal covariates.

Results

Out of 498 individuals screened, 452 participants were analyzed. Vitamin D deficiency was observed in 49% participants, with hyperhomocysteinemia in 34%, dual-risk in 22%, and executive dysfunction in 38% participants. Non-linear associations were evident for both biomarkers (p_non-linear ≤0.04). Adjusted odds of executive dysfunction were 1.61 (95% CI 1.2 to 2.2) at 25(OH)D = 15 vs. 30 ng/mL and 1.4 (1.1 to 2.0) at homocysteine 18 vs. 10 μmol/L. Relative to neither risk, dual-risk had OR 2.1 (1.5 to 2.9) with multiplicative interaction (p = 0.03) and additive synergy (excess risk due to interaction 0.45, 95% CI 0.06 to 0.95).

Conclusion

In older hypertensive inpatients, lower 25(OH)D and higher homocysteine are non-linearly associated with executive dysfunction, and co-occurrence confers excess risk beyond individual effects. Assessing both biomarkers may enhance risk stratification and guide trials of combined correction.

Read the full paper

Introduction

Executive dysfunction in older adults with hypertension is a significant public health concern due to its impact on self-management and adverse health outcomes. Hypertension, prevalent in two-thirds of individuals over 60, is a major risk factor for cognitive decline, including executive dysfunction (1, 2). The cognitive decline associated with hypertension often affects the frontal lobe, leading to impairments in decision-making, planning, and organizing (3 to 5). Furthermore, cognitive impairments can hinder the ability of older adults to engage in health-promoting behaviors (6).

Effective management of hypertension in older adults requires an individualized approach that considers cognitive status (1, 7). Therefore, addressing executive dysfunction through interventions such as cognitive training, the use of organizational aids, and patient-centered care strategies could enhance self-management capabilities and improve health outcomes in older adults with hypertension (5, 8).

Low levels of 25-hydroxyvitamin D [25(OH)D] and elevated homocysteine (Hcy) are implicated in mechanisms that contribute to endothelial injury and white matter compromise, which are critical pathways affecting executive control. Elevated homocysteine levels, known as hyperhomocysteinemia (HHcy), are associated with oxidative stress, neuroinflammation, and endothelial dysfunction, all of which contribute to the disruption of the blood: brain barrier and neurodegeneration, thereby increasing the risk of neurovascular diseases such as stroke and vascular dementia (9, 10). HHcy is also linked to the pathogenesis of Alzheimer’s disease through mechanisms such as tau phosphorylation, beta-amyloid aggregation, and neurofibrillary tangle formation, which are exacerbated by oxidative stress and neuroinflammation (3, 10).

These processes highlight the role of HHcy in promoting vascular dysfunction and neurodegenerative changes, which are critical to the development of cognitive impairments (11, 12). On the other hand, vitamin D deficiency is associated with increased risks of cardiovascular and neurodegenerative diseases due to its role in maintaining endothelial function and reducing oxidative stress and inflammation (13). Low 25(OH)D levels are correlated with more severe white matter hyperintensities and cognitive decline (14). The neurovascular unit, which includes oligodendrocytes responsible for myelinating axons, is particularly vulnerable to ischemic damage, and vitamin D plays a protective role in maintaining myelin integrity and reducing white matter injury (15).

Thus, both low 25(OH)D and elevated Hcy contribute to vascular and neuroinflammatory pathways that compromise myelin integrity and cognitive function (16), and consistent with a cerebrovascular pathway, lower 25(OH)D has also been associated with higher stroke risk (17).

Building on evidence that vitamin D deficiency and hyperhomocysteinemia may affect vascular and white-matter pathways relevant to executive control, our objective was to characterize the associations of serum 25(OH)D and plasma Hcy with executive dysfunction and to test their joint effects on both multiplicative and additive scales in older hypertensive inpatients.

Methods

Study design and participants

We enrolled consecutive inpatients aged ≥60 years with physician-diagnosed hypertension between November 2023 and July 2024. The protocol was approved by the institutional ethics committee of the Affiliated Hospital of Hebei University, and all participants provided written informed consent. The study conformed to the Declaration of Helsinki and local regulations for human research.

Patients were ineligible if they had (i) acute stroke or TIA under evaluation or confirmed within the prior 30 days (neuroimaging/neurology note), (ii) current delirium by a standardized screen at the time of cognitive testing (3D-CAM on wards or CAM-ICU in monitored settings), (iii) deep/ongoing sedation [continuous sedative infusion or Richmond Agitation-Sedation Scale (RASS) ≤ −2], (iv) severe sensory/motor barriers precluding valid testing, or (v) inability to communicate in Mandarin/local dialect. Patients with remote ischemic stroke/TIA remained eligible with a history recorded for analysis.

Those with transient delirium or recent procedural sedation were deferred and re-approached once delirium screens were negative and washout criteria were met.

Setting and procedures

Participants were recruited from inpatient medical wards where admissions reflect the evaluation and management of hypertension and common comorbidities. Because acute delirium, active cardiorespiratory decompensation, or sedative medications can transiently affect cognitive performance, we applied prespecified acute-illness safeguards to ensure testing occurred under clinically stable conditions. All testing occurred within 72 h of admission and after acute-illness safeguards: examiners performed a brief neuro check and a delirium screen (3D-CAM/CAM-ICU) immediately pre-test. If an individual was positive, the test was postponed ≥24 h until two consecutive negative screens.

To minimize sedative carryover, assessments were scheduled ≥6 h after the last IV sedative/benzodiazepine/opioid dose and ≥12 h after the discontinuation of continuous infusions. Pre-test RASS had to be ≥−1. We abstracted sedation exposure from the medication administration record (any benzodiazepine/opioid in prior 24 h; propofol/dexmedetomidine infusion hours in prior 24 h). We captured acute-infection markers within 24 h of testing: temperature, WBC count, C-reactive protein (CRP), procalcitonin, antibiotic initiation and positive cultures: and cardiorespiratory decompensation proxies (SpO2, supplemental O2, systolic BP).

Exposures and laboratory measurements

Primary exposures were serum 25(OH)D and plasma total homocysteine, analyzed in the hospital’s central laboratory with internal quality control during each shift and quarterly external proficiency testing. Serum 25(OH)D was quantified using a chemiluminescent immunoassay on an automated analyzer (Beckman Coulter Access). Plasma total homocysteine was quantified using an enzymatic cycling assay (Diazyme Homocysteine Enzymatic Assay). Serum folate and vitamin B12 were measured using an Abbott ARCHITECT i. Serum creatinine was measured using Creatinine plus (CREP2) on cobas c/COBAS INTEGRA, and eGFR was calculated from creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

Whole blood was centrifuged for 2 h. Serum/plasma aliquots were analyzed on the day of draw. A priori, clinical cut points defined vitamin D deficiency as 25(OH)D < 20 ng/mL (18) and HHcy as homocysteine ≥15 μmol/L. These were combined into a four-level “dual-risk” variable (neither, vitamin D deficiency only, HHcy only, both). To adjust for seasonal variation in 25(OH)D, the calendar month of blood draw was categorized into winter, spring, summer, or autumn for covariate adjustment and sensitivity analyses.

Executive function (EF) was assessed with the Trail Making Test-B (TMT-B), Stroop Color-Word interference, Digit Symbol Substitution (DSST), and Category Fluency. Each raw score was converted to age−/education-adjusted normative T-scores (mean 50, SD 10) using published test norms appropriate for our setting. Directionality was aligned so higher T indicates better performance. The EF composite T-score was the mean of available component T-scores when ≥3 tests were valid. The primary binary outcome (executive dysfunction_norm) was composite T ≤ 40 (≥1 SD below norms, consistent with mild executive impairment), with T ≤ 35 examined as a more stringent threshold in sensitivity analyses.

To facilitate comparability with prior inpatient studies, we also constructed a sample-standardized composite z-score and defined executive dysfunction_z as z ≤ −0.3; this moved to a prespecified sensitivity analysis. All scoring was reviewed by a supervising neuropsychologist.

Covariates

The prespecified adjustment set retained age, sex, education, BMI, systolic BP, diabetes, eGFR modeled continuously with restricted cubic splines, smoking, vitamin D supplementation, B-vitamin supplementation, and season of draw. To address acute-care context, we specified context-robust models that additionally included: history of ischemic stroke/TIA (yes/no), sedation exposure (any benzodiazepine/opioid in prior 24 h or any sedative infusion in prior 24 h; yes/no), and infection burden captured as a composite indicator (fever ≥38.0 °C, WBC ≥ 12 × 109/L, CRP ≥ 10 mg/L, procalcitonin ≥0.25 ng/mL, or new systemic antibiotics within 24 h; yes/no).

These variables were abstracted from the EHR around the cognitive testing timestamp.

Statistical analysis

Baseline characteristics were summarized using means with standard deviations (SDs) or medians with interquartile ranges (IQRs) for continuous variables and counts with whole-number percentages for categorical variables. Group differences were determined using ANOVA or Kruskal: Wallis tests for continuous variables and χ2 tests for categorical variables, with Benjamini: Hochberg false discovery rate (FDR). Primary analyses modeled associations of 25(OH)D and Hcy with executive dysfunction using multivariable logistic regression with restricted cubic splines (RCS; four knots at Harrell percentiles: 5th, 35th, 65th, and 95th), fixing reference values at 30 ng/mL for 25(OH)D and 10 μmol/L for Hcy.

Joint effects were estimated with the four-level exposure, and multiplicative interaction was tested via a product term in fully adjusted models. Additive interaction was quantified from robust Poisson regression with log link and sandwich variance to estimate relative risks and derive the relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (S) with 95% CIs via the delta method. Model diagnostics included inspection of leverage and influence (Δβ and Cook’s distance), assessment of multicollinearity (variance inflation factors <2), and checks for spline overfitting by comparing Akaike information criteria across knot specifications.

Two-sided α = 0.05 defined statistical significance, and analyses were performed in R (Version 4.4).

Sensitivity analyses

Robustness was evaluated by varying the executive dysfunction threshold to composite z ≤ −0.5 and ≤ −0.7, altering spline flexibility by moving knots to quintiles and, separately, refitting with three and five knots, trimming extreme biomarker values by excluding the <1st and >99th percentiles, excluding users of vitamin D and, separately, B-vitamin supplements, and expanding the adjustment set to include folate and vitamin B12 concentrations. The direction and magnitude of primary inferences were stable across these checks.

Results

Participant flow and sample characteristics

Of 498 admissions screened, 486 individuals were eligible, 462 consented, and 452 were included in the analytic cohort after exclusion for incomplete cognitive testing (n = 6) and unusable assays (n = 4) (Figure 1). The mean age was 72 ± 7 years, and 53% were women. Vitamin D deficiency occurred in 49% (n = 222), hyperhomocysteinemia in 34% (n = 155), and dual-risk in 22% (n = 99), while executive dysfunction prevalence was 38% (n = 172) (Table 1).

Counts across the four dual-risk categories were: neither in 174, vitamin D deficiency in 123, hyperhomocysteinemia in 56, and both in 99 (Table 1).

Figure 1

Study flow diagram. Flow of participants from screening to analysis. Final analytic sample n = 452.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Baseline characteristics by vitamin D/homocysteine dual-risk categories.

CharacteristicOverall (n = 452)Neither (n = 174)VitD-only (n = 123)HHcy-only (n = 56)Both (n = 99) p q
Age, y (mean ± SD)72 ± 771 ± 672 ± 674 ± 773 ± 70.040.06
Female, n (%)240 (53%)100 (57%)73 (59%)20 (36%)47 (48%)0.0030.01
Education ≤9 y, n (%)238 (53%)80 (46%)70 (57%)31 (55%)57 (58%)0.020.04
BMI, kg/m2 (mean ± SD)25 ± 425 ± 425 ± 425 ± 424 ± 40.110.15
SBP, mmHg (mean ± SD)142 ± 17141 ± 16143 ± 17144 ± 18145 ± 180.090.13
Diabetes, n (%)124 (27%)40 (23%)36 (29%)17 (30%)31 (31%)0.140.18
Chronic kidney disease, n (%)91 (20%)27 (16%)23 (19%)15 (27%)26 (26%)0.010.03
Current smoker, n (%)98 (22%)31 (18%)22 (18%)20 (36%)25 (25%)0.0040.01
Vitamin B12, pmol/L [median (IQR)]340 [260 to 460]352 [272 to 466]338 [252 to 450]320 [238 to 430]312 [232 to 420]0.080.12
Folate, ng/mL [median (IQR)]7.8 [5.6 to 10.2]8.0 [6.0 to 10.5]7.6 [5.4 to 9.9]7.2 [5.1 to 9.5]7.0 [4.9 to 9.3]0.0480.07
eGFR, mL/min/1.73 m2 [median (IQR)]74 [61 to 86]77 [64 to 89]73 [60 to 85]70 [57 to 82]69 [56 to 81]0.0070.02
25(OH)D, ng/mL [median (IQR)]21.4 [14.8 to 28.3]27.6 [23.1 to 33.9]14.6 [11.9 to 17.6]26.0 [20.8 to 31.8]13.8 [11.1 to 17.1]<0.001<0.001
Homocysteine, μmol/L [median (IQR)]14.2 [11.0 to 18.7]11.2 [9.4 to 12.7]12.1 [10.3 to 14.3]18.1 [16.2 to 21.8]19.3 [16.8 to 23.7]<0.001<0.001
Vitamin D supplement use, n (%)66 (15%)32 (18%)8 (7%)10 (18%)16 (16%)0.0030.01
B-vitamin supplement use, n (%)57 (13%)19 (11%)12 (10%)12 (21%)14 (14%)0.030.048
Executive dysfunction, n (%)172 (38%)47 (27%)48 (39%)20 (36%)57 (58%)<0.001<0.001

VitD-only, vitamin D deficiency only; HHcy-only, hyperhomocysteinemia only; eGFR, estimated glomerular filtration rate (mL/min/1.73 m2).

Baseline characteristics across dual-risk categories

Participants with both risks had higher current smoking (25%) and CKD (eGFR <60 mL/min/1.73 m2) prevalence (26%) and lower eGFR [median 69 mL/min/1.73 m2 (56 to 81)] than those with neither risk [current smoking 18%; CKD 16%; eGFR 77 mL/min/1.73 m2 (64 to 89); p = 0.004, 0.01, and 0.007; FDR-adjusted q = 0.01, 0.03, and 0.02]. Women were less prevalent in the hyperhomocysteinemia-only group (36%), contributing to overall sex differences (p = 0.003; q = 0.01). Folate and vitamin B12 trended lower with increasing risk burden (folate p = 0.048; q = 0.070; B12 p = 0.08; q = 0.12), and supplementation patterns were imbalanced, with fewer vitamin D supplement users in the vitamin D-deficient only group (7%) and more B-vitamin use in the hyperhomocysteinemia-only group (21%; p = 0.003 and 0.03; q = 0.01 and 0.048).

As constructed, 25(OH)D and Hcy levels showed marked gradients across categories (both p < 0.001; q < 0.001). Executive dysfunction prevalence rose stepwise from 27% in the neither group to 39% in vitamin D deficiency only, 36% in hyperhomocysteinemia only, and 58% in the dual-risk group (p < 0.001; q < 0.001), matching a priori risk expectations (Table 1).

Non-linear dose: response associations of biomarkers with executive dysfunction

Restricted cubic spline models demonstrated non-linear relationships between both biomarkers and executive dysfunction after multivariable adjustment (Table 2, Figure 2). For 25(OH)D, the global non-linearity test was significant (p = 0.02; q = 0.03), with risk increasing steeply below approximately 20 ng/mL and flattening above 30 to 40 ng/mL. Relative to 30 ng/mL, the adjusted OR at 15 ng/mL was 1.6 (95% CI 1.2 to 2.2; p = 0.003; q = 0.009), and at 10 ng/mL the OR reached 2.0 (1.3 to 2.9).

For homocysteine, non-linearity was also significant (p = 0.04; q = 0.049), with relatively flat risk at lower concentrations and a monotonic rise beyond approximately 15 μmol/L; the adjusted OR at 18 μmol/L vs. 10 μmol/L was 1.4 (1.1 to 2.0; p = 0.02; q = 0.048), increasing to 1.7 (1.1 to 2.5) at 22 μmol/L.

Table 2

Associations of 25(OH)D and homocysteine with executive dysfunction.

Exposure and specificationAdjusted OR (95% CI) p q
Non-linear dose: response (RCS; 4 knots)Not reported0.020.03
25(OH)D: test of non-linearityNot reported0.040.049
Hcy: test of non-linearity
Prespecified contrasts (continuous)1.6 (1.2 to 2.2)0.0030.009
25(OH)D 15 vs. 30 ng/mL1.4 (1.1 to 2.0)0.020.048
Hcy 18 vs. 10 μmol/L
Binary categories1.5 (1.1 to 2.2)0.020.03
Vitamin D deficiency (<20 vs. ≥20 ng/mL)1.4 (1.0 to 2.0)0.0450.06
Hyperhomocysteinemia (≥15 vs. <15 μmol/L)
Four-level dual-risk (ref = Neither)1.4 (1.0 to 2.0)0.070.08
VitD-only1.3 (0.8 to 2.1)0.230.23
HHcy-only2.1 (1.5 to 2.9)<0.001<0.001
Both (double-risk)Not reported0.030.04
Multiplicative interaction (product term)Not reported0.020.03

CI, confidence interval; HHcy, hyperhomocysteinemia; OR, odds ratio; RCS, restricted cubic splines.

Figure 2

(A) Non-linear association of 25(OH)D with executive dysfunction. Adjusted odds ratios (ORs) from logistic models with restricted cubic splines (four knots); reference fixed at 30 ng/mL. Shaded band: 95% CI. Test of non-linearity p = 0.02; prespecified contrast 15 vs. 30 ng/mL OR 1.6 (95% CI 1.2 to 2.2). Covariates as in Methods. (B) Non-linear association of homocysteine with executive dysfunction. Adjusted ORs from spline models; reference 10 μmol/L. Shaded band: 95% CI. Test of non-linearity p = 0.04; prespecified contrast 18 vs. 10 μmol/L OR 1.4 (95% CI 1.1 to 2.0). 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio; CI, confidence interval.

Figure image at the original source: open the original paper. This file is not included in this text import.

Joint effects of vitamin D deficiency and hyperhomocysteinemia

Relative to participants with neither risk, those with both risks exhibited more than 2-fold higher odds of executive dysfunction (adjusted OR 2.1, 95% CI 1.5 to 2.9; p < 0.001; q < 0.001), whereas point estimates were smaller and not statistically significant for the single-risk categories (vitamin D deficiency only OR 1.4, 95% CI 1.0 to 2.0; p = 0.07; q = 0.08; hyperhomocysteinemia only OR 1.3, 95% CI 0.8 to 2.1; p = 0.23; q = 0.23). A formal product-term test supported multiplicative interaction between deficiency and hyperhomocysteinemia (p = 0.03; q = 0.04).

Translating relative to absolute risk at the sample-mean covariate profile, predicted executive dysfunction probabilities were 29% (95% CI 23 to 35) for neither, 37% (30 to 44) for vitamin D deficiency only, 35% (26 to 45) for hyperhomocysteinemia only, and 52% (43 to 61) for both (Figure 3).

Figure 3

Joint effects of vitamin D deficiency and hyperhomocysteinemia on executive dysfunction. Forest plot shows adjusted ORs (95% CI) for four exposure categories (reference: neither risk), with marginal predicted executive dysfunction probabilities annotated. Double-risk OR 2.1 (95% CI 1.5 to 2.9); multiplicative interaction p = 0.03. executive dysfunction; OR, odds ratio; CI, confidence interval.

Figure image at the original source: open the original paper. This file is not included in this text import.

Additive interaction

On the additive scale, robust Poisson models indicated positive biological interaction between vitamin D deficiency and HHcy (Table 3). The relative excess risk due to interaction (RERI) was 0.45 (95% CI 0.06 to 0.95; p = 0.03; q = 0.04), the attributable proportion (AP) was 0.22 (0.03 to 0.39; p = 0.03; q = 0.04), and the synergy index (S) was 1.5 (1.1 to 2.1; p = 0.03; q = 0.04), indicating that approximately one-fifth of risk among dually exposed patients reflects excess risk beyond the sum of individual effects (Table 3, Figure 3).

Table 3

Additive interaction between vitamin D deficiency and hyperhomocysteinemia for executive dysfunction.

Metric (ref = Neither)Estimate (95% CI) p q
RERI (excess risk due to interaction)0.45 (0.06 to 0.95)0.030.04
Attributable proportion (AP)0.22 (0.03 to 0.39)0.030.04
Synergy index (S)1.5 (1.1 to 2.1)0.030.04

Executive dysfunction; CI, confidence interval; RERI, relative excess risk due to interaction; AP, attributable proportion; S, synergy index.

Sensitivity analyses

Robustness checks confirmed that the main inferences did not depend on the outcome definition, kidney-function covariate, or inpatient context (Supplementary Tables S1, S2) (Supplementary Tables S1, S2). Using stricter executive dysfunction thresholds (z ≤ −0.5 and z ≤ −0.7) yielded the same non-linear patterns for both biomarkers [25(OH)D non-linearity p = 0.02 to 0.01; Hcy p = 0.04 to 0.03; all q ≤ 0.05] with contrasts similar to the primary analysis: 25(OH)D 15 vs. 30 ng/mL OR 1.6 to 1.7 and Hcy 18 vs. 10 μmol/L OR 1.4 to 1.5: and preserved the joint “double-risk” association (OR 2.1 to 2.2) together with multiplicative interaction (p = 0.03 to 0.02; q ≤ 0.05) and positive additive interaction (RERI 0.47 to 0.55) (Supplementary Tables S1, Panel A).

Representing renal function as CKD (eGFR<60 mL/min/1.73 m2) instead of the eGFR-spline produced materially similar estimates [25(OH)D OR 1.6; Hcy OR 1.4; double-risk OR 2.0; product-term p = 0.04; RERI 0.44], supporting the choice to model kidney function once, continuously (Supplementary Tables S1, Panel B). Context-robust models that added prior stroke/TIA, recent sedation exposure, and infection burden, as well as a restricted analysis excluding any sedation/infection in the prior 24 h, closely matched the primary results [25(OH)D OR 1.6 to 1.7; Hcy OR 1.4 to 1.5; double-risk OR 2.0 to 2.1; product-term p = 0.03 to 0.02; RERI 0.43 to 0.47], indicating that acute-care factors did not account for the observed non-linear associations or the excess risk in the double-risk group (Supplementary Table S2).

Discussion

In this cross-sectional cohort study, we found that both lower 25(OH)D and higher Hcy were related to executive dysfunction in distinctly non-linear patterns. Crucially, when both abnormalities co-occurred (“double-risk”), the association exceeded individual effects: compared with patients with neither risk, the double-risk group had more than 2-fold higher odds of executive dysfunction.

Placed alongside prior studies, our results extend observational associations between low 25(OH)D and poorer executive performance and faster decline, and between higher Hcy and heavier cSVD/white-matter burdens, by revealing where along each continuum risk accelerates and by quantifying biological interaction between the two pathways (19 to 25). Studies in community and patient cohorts link low 25(OH)D to worse cognition and increased dementia risk, while neuroimaging reports connect low 25(OH)D and high Hcy to more white-matter hyperintensities and microstructural compromise: lesions that map onto executive control networks (19 to 25).

Methodologically, modeling with restricted cubic splines avoids the information loss and bias of linear or dichotomized exposures and makes the inflection zones explicit, and estimating additive-scale interaction (RERI, attributable proportion, synergy index) addresses whether the “double-risk” exceeds the sum of individual effects (26 to 28). Our spline-based contrasts and significant additive/multiplicative interaction, therefore, add granularity beyond much of the existing vitamin D/Hcy: cognition literature.

Clinically, our data support early inpatient assessment of both biomarkers in older adults with hypertension to refine cognitive risk stratification and to identify patients most likely to benefit from intervention (18, 29 to 33). In hypertensive populations, achieving 25(OH)D status has been linked to blood pressure measures in community supplement programs (34), and meta-analytic evidence suggests vitamin D supplementation may modestly reduce systolic blood pressure in hypertensive individuals with hypovitaminosis D (35). For homocysteine-lowering, the China Stroke Primary Prevention Trial (CSPPT) randomized hypertensive adults to enalapril plus folic acid vs. enalapril alone and reported reduced first stroke, whereas the Heart Outcomes Prevention Evaluation-2 (HOPE-2) trial tested folic acid/B-vitamin therapy in vascular disease and reported mixed cardiovascular outcomes but fewer strokes (36, 37).

Recent randomized controlled trial evidence suggests vitamin D supplementation does not improve executive function in older adults with mild cognitive impairment (38), and a recent meta-analysis suggests B-vitamin supplementation may have small effects on global cognitive function in older adults (39). Together, these data motivate factorial trials testing simultaneous vitamin D repletion and homocysteine-lowering on executive outcomes (and MRI white-matter endpoints) on top of guideline blood pressure control, enriched for patients who exhibit the dual-risk pattern.

Our findings point to a vascular-white-matter pathway linking both low 25(OH)D and elevated Hcy to executive dysfunction in older adults with hypertension. Risk rose steeply once 25(OH)D dropped into deficient ranges and as Hcy exceeded clinically used cutpoints, consistent with the biology that vitamin D restrains renin: angiotensin signaling and supports endothelial nitric oxide bioavailability, whereas Hcy impairs the nitric-oxide pathway via asymmetric dimethylarginine, promoting endothelial injury and prothrombotic tone (29 to 32). In cerebral small-vessel disease, endothelial failure, blood: brain barrier leak, and hypoperfusion render frontal: subcortical white matter especially vulnerable, providing a substrate for executive dysfunction (40 to 43).

This mechanistic arc explains the non-linear dose: response we observed for both biomarkers and the excess risk when deficiency and hyperhomocysteinemia co-occur, with predicted executive dysfunction probabilities rising from 29% (neither risk) to 52% (double-risk) in our cohort. The inflection zones align with widely adopted thresholds [25(OH)D < 20 ng/mL; Hcy ≥ 15 μmol/L] at which endothelial and white-matter injury patterns intensify (18, 29 to 33, 40 to 43).

Nonetheless, limitations warrant a cautious interpretation of our findings. The cross-sectional design precludes causal inference and leaves open reverse causation (e.g., illness severity influencing nutritional status or homocysteine). Residual confounding remains possible despite adjustment (e.g., sun exposure, dietary folate/B12, parathyroid hormone, and inflammatory status). Findings derive from a single-center inpatient population and may not generalize to community or outpatient settings. Single-time biomarker measurements are vulnerable to short-term variability and seasonality despite seasonal adjustment and sensitivity analyses. Complete-case primary models, with multiple imputation as a check, reduce but cannot eliminate bias from missingness.

Taken together, these strengths support the credibility of the observed non-linear associations and dual-scale interaction, while the limitations emphasize the need for multicenter, longitudinal studies with repeated biomarker assessments and mechanistic imaging to establish temporality and transportability.

In older hypertensive inpatients, lower 25-hydroxyvitamin D and higher homocysteine relate to executive dysfunction in non-linear patterns, and their co-occurrence confers excess risk beyond individual effects. Early inpatient assessment of both biomarkers can refine cognitive risk stratification and highlight patients most likely to benefit from targeted therapy. These findings support multicenter longitudinal studies and randomized factorial trials testing combined vitamin D repletion and homocysteine-lowering alongside guideline blood-pressure control.

Edited by: Ronan Lordan, Royal College of Surgeons in Ireland, Ireland

Reviewed by: William B. Grant, Sunlight Nutrition and Health Research Center, United States

Neluwa-Liyanage Indika, University of Sri Jayewardenepura, Sri Lanka

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by the protocol conformed to the Declaration of Helsinki and was approved by the ethics committee of Affiliated Hospital of Hebei University. All participants provided written informed consent prior to any study procedures. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

LT: Investigation, Writing: original draft. LZ: Investigation, Methodology, Writing: original draft. HL: Methodology, Writing: original draft. YZ: Conceptualization, Writing: review & editing. YC: Conceptualization, Funding acquisition, Writing: review & editing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2025.1718923/full#supplementary-material

Supplement file at the original source: open the original paper. This file is not included in this text import.
Supplement file at the original source: open the original paper. This file is not included in this text import.

References

1. Zamora Z Williamson J . Hypertension In: Busby-Whitehead J Durso SC Arenson C Elon R Palmer MH Reichel W , editors. Reichel’s care of the elderly: clinical aspects of aging . Cambridge: Cambridge University Press (2022 ). 173Not reported9 .
2. Ungvari Z Toth P Toth P Toth P Tarantini S Tarantini S . Hypertension-induced cognitive impairment: from pathophysiology to public health . Nat Rev Nephrol . (2021 ) 17 :639Not reported54 . doi: 10.1038/S41581-021-00430-6 , 34127835 PMC8202227
3. Cheon EJ . Hypertension and cognitive dysfunction: a narrative review . J Yeungnam Med Sci . (2023 ) 40 :225Not reported32 . doi: 10.12701/jyms.2022.00605 , 36443940 PMC10390283
4. Munshi M Hayes M Iwata I Lee Y Weinger K Weinger K . Which aspects of executive dysfunction influence ability to manage diabetes in older adults . Diabet Med . (2012 ) 29 :1171Not reported7 . doi: 10.1111/J.1464-5491.2012.03606.X , 22340082
5. Alosco ML Spitznagel MB Spitznagel MB Raz N Cohen RA Sweet LH . Executive dysfunction is independently associated with reduced functional independence in heart failure . J Clin Nurs . (2014 ) 23 :829Not reported36 . doi: 10.1111/JOCN.12214 , 23650879 PMC5022367
6. Kordovski VM Tierney SM Rahman S Medina LD Babicz MA Yoshida H . Older age and online health information search behaviors: the mediating influence of executive functions . J Clin Exp Neuropsychol . (2021 ) 43 :689Not reported703 . doi: 10.1080/13803395.2021.1990866 , 34730068
7. Spinelli C De Caro M Schirosi G Mezzapesa DM De Benedittis L Chiapparino C . Impaired cognitive executive dysfunction in adult treated hypertensives with a confirmed diagnosis of poorly controlled blood pressure . Int J Med Sci . (2014 ) 11 :771Not reported8 . doi: 10.7150/IJMS.8147 , 24936139 PMC4057488
8. Gerber LM Barrón Y Mongoven JM McDonald MV Henriquez E Andreopoulos E . Activation among chronically ill older adults with complex medical needs: challenges to supporting effective self-management . J Ambul Care Manage . (2011 ) 34 :292Not reported303 . doi: 10.1097/JAC.0B013E31821C63B1 21673530
9. Ortiz-Salguero C Romero-Bernal M González-Díaz Á Doush E del Río C Echevarría M . Hyperhomocysteinemia: underlying links to stroke and hydrocephalus, with a focus on polyphenol-based therapeutic approaches . Nutrients . (2024 ) 17 :40 . doi: 10.3390/nu17010040 , 39796474 PMC11722995
10. Smith AD Refsum H . Homocysteine: from disease biomarker to disease prevention . J Intern Med . (2021 ) 290 :826Not reported54 . doi: 10.1111/joim.13279 , 33660358
11. Bonetti F Brombo G Zuliani G . The relationship between hyperhomocysteinemia and neurodegeneration . Neurodegener Dis Manag . (2016 ) 6 :133Not reported45 . doi: 10.2217/NMT-2015-0008 , 27033101
12. Li S Li G Luo X Huang Y Wen L Li J . Endothelial dysfunction and hyperhomocysteinemia-linked cerebral small vessel disease: underlying mechanisms and treatment timing . Front Neurol . (2021 ) 12 :736309 . doi: 10.3389/FNEUR.2021.736309 , 34899561 PMC8651556
13. Kim HA Kim HA Perrelli A Ragni A Retta F De Silva TM . Vitamin D deficiency and the risk of cerebrovascular disease . Antioxidants . (2020 ) 9 :327 . doi: 10.3390/ANTIOX9040327 32316584 PMC7222411
14. Gu Z Sun X Wu C Li B Chen J Wang W . Lower 25-hydroxyvitamin D is associated with severer white matter hyperintensity and cognitive function in patients with non-disabling ischemic cerebrovascular events . J Stroke Cerebrovasc Dis . (2023 ) 32 :107311 . doi: 10.1016/j.jstrokecerebrovasdis.2023.107311 , 37659193
15. Rosenberg GA Maki T Arai K Lo EH . Gliovascular mechanisms and white matter injury in vascular cognitive impairment and dementia In: Grotta JC Albers GW Broderick JP Kasner SE Lo EH Sacco RL editors. Stroke (seventh edition): pathophysiology, diagnosis, and management . Philadelphia, PA, USA: Elsevier (2022 ). 153Not reported160.e4 . doi: 10.1016/B978-0-323-69424-7.00013-2
16. Moretti R Caruso P Dal Ben M Conti C Gazzin S Tiribelli C . Vitamin D, homocysteine, and folate in subcortical vascular dementia and Alzheimer dementia . Front Aging Neurosci . (2017 ) 9 :169 . doi: 10.3389/FNAGI.2017.00169 , 28611659 PMC5447683
17. Tsai MC Fan HY Hsu HY Tseng PJ Chuang SM Yeh TL . Association of serum 25-hydroxyvitamin D with stroke: observational mediation and Mendelian randomization study . J Clin Endocrinol Metab . (2025 ) 110 :e1420Not reported9 . doi: 10.1210/clinem/dgae561 , 39138829
18. Holick MF Binkley NC Bischoff-Ferrari HA Gordon CM Hanley DA Heaney RP . Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline . J Clin Endocrinol Metab . (2011 ) 96 :1911Not reported30 . doi: 10.1210/jc.2011-0385 , 21646368
19. Buell JS Scott TM Dawson-Hughes B Dallal GE Rosenberg IH Folstein MF . Vitamin D is associated with cognitive function in elders receiving home health services . J Gerontol A Biol Sci Med Sci . (2009 ) 64 :888Not reported95 . doi: 10.1093/gerona/glp032 , 19377013 PMC2981461
20. Llewellyn DJ Lang IA Langa KM Muniz-Terrera G Phillips CL Cherubini A . Vitamin D and risk of cognitive decline in elderly persons . Arch Intern Med . (2010 ) 170 :1135Not reported41 . doi: 10.1001/archinternmed.2010.173 , 20625021 PMC4053858
21. Littlejohns TJ Henley WE Lang IA Annweiler C Beauchet O Chaves PH . Vitamin D and the risk of dementia and Alzheimer disease . Neurology . (2014 ) 83 :920Not reported8 . doi: 10.1212/WNL.0000000000000755 , 25098535 PMC4153851
22. Prager JM Thomas C Ankenbrandt WJ Meyer JR Gao Y Ragin A . Association of white matter hyperintensities with low serum 25-hydroxyvitamin D levels . AJNR Am J Neuroradiol . (2014 ) 35 :1145Not reported9 . doi: 10.3174/ajnr.A3840 , 24436348 PMC7965142
23. Zhao Y Xu J Feng Z Wang J . Impact of 25-hydroxy vitamin D on white matter hyperintensity in elderly patients: a systematic review and meta-analysis . Front Neurol . (2022 ) 12 :721427 . doi: 10.3389/fneur.2021.721427 , 35095709 PMC8794798
24. Piao X Wu G Yang P Shen J De A Wu J . Association between homocysteine and cerebral small vessel disease: a meta-analysis . J Stroke Cerebrovasc Dis . (2018 ) 27 :2423Not reported30 . doi: 10.1016/j.jstrokecerebrovasdis.2018.04.035 , 29801814
25. Hsu JL Chen WH Bai CH Leu JG Hsu CY Viergever MA . Microstructural white matter tissue characteristics are modulated by homocysteine: a diffusion tensor imaging study . PLoS One . (2015 ) 10 :e0116330 . doi: 10.1371/journal.pone.0116330 , 25693199 PMC4334653
26. Desquilbet L Mariotti F . Dose-response analyses using restricted cubic spline functions in public health research . Stat Med . (2010 ) 29 :1037Not reported57 . doi: 10.1002/sim.3841 , 20087875
27. Knol MJ VanderWeele TJ Groenwold RH Klungel OH Rovers MM Grobbee DE . Estimating measures of interaction on an additive scale for preventive exposures . Eur J Epidemiol . (2011 ) 26 :433Not reported8 . doi: 10.1007/s10654-011-9554-9 , 21344323 PMC3115067
28. VanderWeele T Knol M . A tutorial on interaction . Epidemiol Methods . (2014 ) 3 :33Not reported72 . doi: 10.1515/em-2013-0005
29. Li YC Kong J Wei M Chen ZF Liu SQ Cao LP . 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system . J Clin Invest . (2002 ) 110 :229Not reported38 . doi: 10.1172/JCI15219 , 12122115 PMC151055
30. Tarcin O Yavuz DG Ozben B Telli A Ogunc AV Yuksel M . Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects . J Clin Endocrinol Metab . (2009 ) 94 :4023Not reported30 . doi: 10.1210/jc.2008-1212 , 19584181
31. Al Mheid I Patel R Murrow J Morris A Rahman A Fike L . Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans . J Am Coll Cardiol . (2011 ) 58 :186Not reported92 . doi: 10.1016/j.jacc.2011.02.051 , 21718915 PMC3896949
32. Stühlinger MC Tsao PS Her JH Kimoto M Balint RF Cooke JP . Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine . Circulation . (2001 ) 104 :2569Not reported75 . doi: 10.1161/hc4601.098514 , 11714652
33. Li T Liu X Diao S Kong Y Duan X Yang S . H-type hypertension is a risk factor for cerebral small-vessel disease . Biomed Res Int . (2020 ) 2020 :6498903 . doi: 10.1155/2020/6498903 , 32090105 PMC7029257
34. Mirhosseini N Vatanparast H Kimball SM . The association between serum 25(OH)D status and blood pressure in participants of a community-based program taking vitamin D supplements . Nutrients . (2017 ) 9 :1244 . doi: 10.3390/nu9111244 , 29135923 PMC5707716
35. Serra MO de Macedo LR Silva M Lautner RQ . Effect of vitamin D supplementation on blood pressure in hypertensive individuals with hypovitaminosis D: a systematic review and meta-analysis . J Hypertens . (2024 ) 42 :594Not reported604 . doi: 10.1097/HJH.0000000000003646 , 38164948
36. Huo Y Li J Qin X Huang Y Wang X Gottesman RF . Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial . JAMA . (2015 ) 313 :1325Not reported35 . doi: 10.1001/jama.2015.2274 25771069
37. Lonn E Yusuf S Arnold MJ Sheridan P Pogue J Micks M . Homocysteine lowering with folic acid and B vitamins in vascular disease . N Engl J Med . (2006 ) 354 :1567Not reported77 . doi: 10.1056/NEJMoa060900 16531613
38. Corbett A Taylor R Llewellyn D Ranson JM Hampshire A Pickering E . Impact of vitamin D supplementation on cognition in adults with mild to moderate vitamin D deficiency: outcomes from the VitaMIND randomized controlled trial . J Am Med Dir Assoc . (2025 ) 26 :105711 . doi: 10.1016/j.jamda.2025.105711 , 40480279
39. Berg J Grant R Siervo M Stephan BCM Tully PJ . Efficacy of B vitamin supplementation on global cognitive function in older adults: a systematic review and meta-analysis . Nutr Rev . (2025 ) 83 :2256Not reported67 . doi: 10.1093/nutrit/nuaf155 40966571
40. Wardlaw JM Smith C Dichgans M . Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging . Lancet Neurol . (2013 ) 12 :483Not reported97 . doi: 10.1016/S1474-4422(13)70060-7 , 23602162 PMC3836247
41. Debette S Markus HS . The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis . BMJ . (2010 ) 341 :c3666 . doi: 10.1136/bmj.c3666 , 20660506 PMC2910261
42. Sweeney MD Kisler K Montagne A Toga AW Zlokovic BV . The role of brain vasculature in neurodegenerative disorders . Nat Neurosci . (2018 ) 21 :1318Not reported31 . doi: 10.1038/s41593-018-0234-x , 30250261 PMC6198802
43. Thrippleton MJ Backes WH Sourbron S Ingrisch M van Osch MJP Dichgans M . Quantifying blood-brain barrier leakage in small vessel disease: review and consensus recommendations . Alzheimers Dement . (2019 ) 15 :840Not reported58 . doi: 10.1016/j.jalz.2019.01.013 , 31031101 PMC6565805
Publication and source details

Original title: Association of serum 25-hydroxyvitamin D and homocysteine “double-risk” status with executive dysfunction in older adults with hypertension

Lili Tan; Linya Zhao; Hongyan Li; Yamin Zhao; Yinyin Chen

Frontiers in Nutrition · 2026

* Correspondence: Yamin Zhao, hongye8013700@163.com; Yinyin Chen, Chenyinyin0219@163.com
†

These authors have contributed equally to this work

Copyright © 2026 Tan, Zhao, Li, Zhao and Chen.2026Tan, Zhao, Li, Zhao and Chenhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the Baoding Science and Technology Bureau (No. 2341ZF342).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:21:31.354853+00:00

DOI: 10.3389/fnut.2025.1718923 · PMC12855134